LLY vs SLB: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
VS
SLB N.V. · Energy
$56.15
+45.0% upside to fair value
Grade B
QuantHub Verdict
SLB has more upside to fair value
(+45.0%).
SLB trades at a lower forward P/E
(24.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
SLB |
| Current Price |
$934.34 |
$56.15 |
| Fair Value Estimate |
$1,098.43 |
$81.42 |
| Upside to Fair Value |
+17.6%
|
+45.0%
|
| Market Cap |
$882.8B |
$84.3B |
| Forward P/E |
33.1x
|
24.3x
|
| EV / EBITDA |
27.9x
|
17.5x
|
| Price / Sales |
12.2x
|
2.4x
|
| Price / FCF |
65.0x
|
17.6x
|
| Revenue Growth YoY |
+55.5%
|
+2.7%
|
| Gross Margin |
82.7%
|
13.6%
|
| Operating Margin |
46.3%
|
11.5%
|
| Return on Equity |
101.3%
|
12.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
5.69%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
SLB N.V. is the world's largest oilfield services company operating primarily in the energy sector with a focus on oil and gas equipment and services. The company benefits from a diversified revenue base across well construction, production systems, reservoir characterization, and digital integration, with fiscal year 2024 revenues totaling over $37 billion. Despite modest revenue growth of 2.7% …
Accumulation Zones
| Metric |
LLY |
SLB |
| Zone Low |
$823.82 |
$61.06 |
| Zone High |
$933.67 |
$69.21 |
| In Buy Zone? |
No
|
Yes
|